Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
Under the agreement, Vector licenses its proprietary biomechanical peptide delivery platform to LyoGenesis, and in return secures an exclusive, long-term manufacturing relationship covering Vector's proprietary peptide portfolio, which will be sold directly to physicians and clinics. New...
Under the agreement, Vector licenses its proprietary biomechanical peptide delivery platform to LyoGenesis, and in return secures an exclusive, long-term manufacturing relationship covering Vector's proprietary peptide portfolio, which will be sold directly to physicians and clinics. New...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.